Research graph
References from Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Elevated peripheral levels of receptor-interacting protein kinase 1 (RIPK1) and IL-8 as biomarkers of human amyotrophic lateral sclerosis
10.1038/s41392-023-01713-z · 2023 · External reference
Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis
2017 · External reference
Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications
10.3389/fimmu.2017.01005 · 2017 · External reference
The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets
10.3389/fnagi.2024.1347987 · 2024 · External reference
Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target
10.1038/s41573-020-0071-y · 2020 · External reference
Single-cell transcriptomic and functional studies identify glial state changes and a role for inflammatory RIPK1 signaling in ALS pathogenesis
10.1016/j.immuni.2025.02.024 · 2025 · External reference
Identification of RIP1 kinase as a specific cellular target of necrostatins
10.1038/nchembio.83 · 2008 · External reference
Necroptosis drives motor neuron death in models of both sporadic and familial ALS
10.1016/j.neuron.2014.01.011 · 2014 · External reference
Activation of necroptosis in multiple sclerosis
10.1016/j.celrep.2015.02.051 · 2015 · External reference
RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS
10.1126/science.aaf6803 · 2016 · External reference
Necroptosis, a novel type of programmed cell death, contributes to early neural cells damage after spinal cord injury in adult mice
10.1179/2045772314y.0000000224 · 2015 · External reference
Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants
10.1111/cts.13690 · 2024 · External reference
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
10.1080/146608200300079536 · 2000 · External reference
The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function
10.1016/s0022-510x(99)00210-5 · 1999 · External reference
An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis
10.1080/14737175.2023.2174018 · 2023 · External reference
The combined assessment of function and survival (CAFS): a new endpoint for ALS clinical trials
10.3109/21678421.2012.762930 · 2013 · External reference
Association between decline in slow vital capacity and respiratory insufficiency, use of assisted ventilation, tracheostomy, or death in patients with amyotrophic lateral sclerosis
10.1001/jamaneurol.2017.3339 · 2018 · External reference
Quantitative strength testing in ALS clinical trials
10.1212/wnl.0000000000002941 · 2016 · External reference
Usefulness of the ALSAQ-5 scale in evaluation of quality of life in amyotrophic lateral sclerosis
10.1016/s0028-3843(14)60153-5 · 2010 · External reference
Longitudinal biomarkers in amyotrophic lateral sclerosis
10.1002/acn3.51078 · 2020 · External reference
Clinical significance in the change of decline in ALSFRS-R
10.3109/17482960903093710 · 2010 · External reference
Unresolved reference
2018 · External reference
Inflammatory checkpoints in amyotrophic lateral sclerosis: From biomarkers to therapeutic targets
10.3389/fimmu.2022.1059994 · 2022 · External reference
A RIPK1-regulated inflammatory microglial state in amyotrophic lateral sclerosis
10.1073/pnas.2025102118 · 2021 · External reference
The metabolic intersection between immunosenescence and neuroinflammation in amyotrophic lateral sclerosis
10.1186/s12950-025-00460-y · 2025 · External reference
Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain
10.1155/2013/480739 · 2013 · External reference
Are circulating cytokines reliable biomarkers for amyotrophic lateral sclerosis?
10.3390/ijms20112759 · 2019 · External reference
Diagnostic delay in amyotrophic lateral sclerosis
10.1111/ene.15874 · 2023 · External reference
Long-term safety and efficacy of lecanemab in early Alzheimer's disease: results from the Clarity AD open-label extension study
10.1002/alz.70905 · 2025 · External reference
A controlled trial of riluzole in amyotrophic lateral sclerosis
10.1056/nejm199403033300901 · 1994 · External reference
Analysis of start-up, retention, and adherence in ALS clinical trials
10.1212/wnl.0b013e3182a823e0 · 2013 · External reference
